<DOC>
	<DOCNO>NCT02914340</DOCNO>
	<brief_summary>This multicenter , prospective study design evaluate performance SVS REACH SVS control patient . The study expect enroll 20 patient 12 site 6 patient per site .</brief_summary>
	<brief_title>REACH SVS Control Patient Cross-Over Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Patient enrol REACH SVS Study control group complete participation Study include 12 month followup visit . Patient receive standardofcare medical management stable 6 week . Patient willing participate study , complete require followup visit , maintain consistent nutrition exercise habit study period . Patient classify ASA Class great P4 include presence comorbidity could significantly increase risk bronchoscopy procedure . Patient participate study investigational drug device within past 30 day prior participation study . Patient demonstrate unwillingness inability complete baseline data collection procedure . Patient coexist major medical disease limit evaluation , participation , followup study . Patient unable provide inform consent . Patient appropriate candidate unable tolerate , flexible bronchoscopy procedure . Patient history 4 hospitalization COPD exacerbation respiratory infection past year none occur prior 3 month . Patient evidence systemic disease neoplasia expect compromise survival 3month study period Patient demonstrate unwillingness inability complete screen baseline data collection procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>